Triumeq vs Truvada

Listen to the article instead of reading through it.

0:00

Introduction

For patients diagnosed with HIV or at high risk of contracting the virus, certain antiretroviral medications can help manage the condition by reducing viral loads and preventing the progression to AIDS. Triumeq and Truvada are two such drugs that are often prescribed for this purpose. They each impact different stages of the HIV life cycle but both have effects in managing patient's viral load and improving immune function.

Triumeq is a combination drug containing abacavir, dolutegravir, and lamivudine which disrupts multiple phases of viral replication including reverse transcription and integration into host DNA. On the other hand, Truvada consists of emtricitabine and tenofovir disoproxil fumarate which primarily work as nucleoside reverse transcriptase inhibitors (NRTIs), disrupting the process where HIV RNA is converted into DNA. Both medication regimens require strict adherence to maintain their effectiveness against HIV.

What is Triumeq?

Abacavir/dolutegravir/lamivudine (the generic name for Triumeq) is a potent combination of three different types of antiretroviral drugs, marking significant progress from the earlier class of HIV medications. It was first approved by the FDA in 2014. Triumeq works by preventing the replication of HIV-1 in your body, effectively "trapping" it and preventing its spread. This medication is prescribed for people who are living with HIV and need to control their viral load. The unique combination found in Triumeq has a selective influence on reverse transcriptase and integrase, two enzymes crucial to the life cycle of HIV, with only minor influences elsewhere - this results in fewer side effects than other antiretrovirals that have stronger effects on these or other bodily functions.

On the other hand, Truvada (emtricitabine/tenofovir disoproxil fumarate) has been around longer as it was approved by FDA back in 2004. Unlike Triumeq which contains three active ingredients, Truvada consists only two but still very effective against controlling HIV-1 infection when used alongside other antiretroviral medications.

What conditions is Triumeq approved to treat?

Triumeq is approved for the treatment of different stages and aspects of HIV:

As initial therapy in antiretroviral-naive adults
In patients with a certain type of HIV genotype (those who are negative for HLA-B*5701)
For virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen at start of therapy.

On the other hand, Truvada is used for:

Treating HIV infection when used along with other medicines
Reducing the risk of getting HIV infection in people who have a high risk.

How does Triumeq help with these illnesses?

Triumeq helps to manage HIV by reducing the amount of virus in the body. It does this through a combination of three different antiretroviral medications: Abacavir, Dolutegravir, and Lamivudine. These drugs work together to inhibit both reverse transcriptase and integrase, two enzymes that HIV uses to reproduce itself within human cells. By blocking these enzymes, Triumeq can limit the multiplication of HIV and help patients manage their condition.

HIV is a virus that attacks the immune system; it specifically targets CD4 cells (T cells), which are crucial for fighting off infections. Because individuals with HIV have relatively lower levels of healthy T cells, they're more vulnerable to other infections and diseases.

Therefore, by decreasing the amount of virus in your body with Triumeq treatment—thus allowing your immune system time to recover—you can better control your overall health while living with an HIV diagnosis.

What is Truvada?

Truvada is a brand name for the combination of two antiretroviral drugs, emtricitabine and tenofovir disoproxil. These are nucleoside reverse transcriptase inhibitors (NRTIs), which mean they prevent the replication of HIV in the body by blocking an essential enzyme, reverse transcriptase. Truvada was first approved by the FDA in 2004 and it's primarily used as a part of antiretroviral therapy for those with HIV infection to reduce their viral load. In addition, it has been approved for pre-exposure prophylaxis (PrEP) to help prevent high-risk individuals from contracting HIV. Unlike Triumeq that contains three active ingredients, Truvada only consists of two medicines. Therefore, its side effect profile can be different than that of Triumeq with less potential drug interactions due to fewer components involved; however, both drugs have their own benefits depending on individual health situations and responses to treatment.

What conditions is Truvada approved to treat?

Truvada is an FDA-approved medication for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age or older. It is widely used as:

One component of a regimen to treat HIV-1 infection
A pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually acquired HIV-1 in individuals at high risk.

How does Truvada help with these illnesses?

Truvada is a combination antiretroviral medication containing two active ingredients, emtricitabine and tenofovir disoproxil fumarate. It works by blocking the action of reverse transcriptase, an enzyme necessary for viral replication in HIV-infected cells. This effectively prevents the virus from multiplying and spreading through the body. Truvada is often prescribed as part of a combined regimen to treat HIV infection or as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition in high-risk individuals. Unlike Triumeq, which contains three different antiviral medications including an integrase inhibitor, Truvada does not significantly affect this enzyme involved in viral replication and may therefore be preferred when patients have certain comorbid conditions or drug sensitivities.

How effective are both Triumeq and Truvada?

Both Triumeq and Truvada are leading antiretroviral medications used in the treatment of HIV, approved by the FDA within a decade of each other. As they act on different stages of viral replication, they may be prescribed under different circumstances or even together for comprehensive treatment. The effectiveness of Triumeq and Truvada was compared directly in several clinical trials such as SINGLE (2013) and ASSERT (2010); both drugs demonstrated high efficacy in reducing viral loads with comparable safety profiles.

A 2015 meta-analysis on dolutegravir-based regimens like Triumeq showcased its rapid suppression of HIV-1 RNA levels from the first week onwards, favorable side effect profile compared to many other antiretrovirals, including fewer kidney-related issues than tenofovir-based therapies like Truvada. It has been widely accepted due to these factors along with its lower pill burden since it's a single-tablet regimen.

On the other hand, a review conducted in 2018 indicated that emtricitabine/tenofovir disoproxil fumarate (Truvada) is highly effective against HIV infection when used consistently and correctly for pre-exposure prophylaxis (PrEP). Despite this efficacy, it's typically considered alongside another antiretroviral medication for complete treatment as part of combination therapy. There is substantial evidence supporting its use both as PrEP among high-risk populations and as part of first-line treatments against established infections. Further research confirms its role alongside other antiretroviral drugs but data proving standalone efficacy are less robust than those available for combination therapies involving more diverse mechanisms.

Nonetheless, due to unique pharmacokinetic properties which allow once-daily dosing without food restrictions unlike abacavir-containing regimens like Triumeq; individuals requiring flexibility or having specific dietary constraints might find Truvada more suitable despite potential renal concerns which require regular monitoring.

abstract image of a researcher studying a bottle of drug.

At what dose is Triumeq typically prescribed?

Oral dosages of Triumeq for adults typically consist of one tablet per day, taken with or without food. For pediatric patients weighing at least 40kg, the same dosage is recommended. Truvada also has a standard dose of one tablet per day for adults and children weighing at least 35kg in combination with other antiretroviral agents. Neither medication's dosage should be increased or decreased without medical consultation due to their potent therapeutic nature and potential side effects. It's vital that both medications are taken consistently as prescribed to maintain their effectiveness in managing HIV-1 infection.

Find Top Clinical Trials

Choose from over 30,000 active clinical trials.

At what dose is Truvada typically prescribed?

Truvada treatment for HIV-1 infection in adults and pediatric patients weighing at least 17 kg is typically started at one tablet (containing 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) taken orally once a day. It's crucial to take Truvada around the same time each day to maintain consistent drug levels in your body, which helps keep the virus under control. For pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1, adults and adolescents who weigh at least 35kg should also take one tablet daily. Patients must be confirmed as being HIV-negative immediately prior to starting Truvada for PrEP. If there is no response or if adverse reactions occur, consult with your healthcare professional regarding adjustments.

What are the most common side effects for Triumeq?

Common side effects of Triumeq can include:

Insomnia (difficulty sleeping)
Headache
Dizziness
Fatigue or weakness
Diarrhea, nausea, and vomiting
Rash
Fever (experiencing symptoms like the flu)
Abdominal pain and bloating

On the other hand, Truvada may cause:

Nausea, vomiting, stomach pain
Diarrhea
Weight loss
Headache or dizziness
Depression or anxiety -Lowered bone density potentially causing brittle bones.

As always any changes in your health while taking these medications should be reported to a healthcare professional promptly.

abstract image of a patient experiencing side effect

Are there any potential serious side effects for Triumeq?

While both Triumeq and Truvada are effective antiretroviral drugs used in the treatment of HIV, there can be some serious side effects associated with each. For instance, with Triumeq:

Severe skin reactions or allergic responses: rashes, itching/swelling (particularly of the face/tongue/throat), severe dizziness and breathing troubles.
Lactic acidosis - a rare metabolic condition that can happen due to cell damage. Symptoms include: trouble breathing; feeling cold in arms or legs; unusual muscle pain; feeling dizzy or light-headed; stomach pains with nausea and vomiting.
Liver problems - signs might include yellowing skin/eyes (jaundice), dark urine, constant fatigue, loss of appetite and abdominal/stomach pain.

With Truvada:

Kidney issues – symptoms may encompass lower back/side pain, changes in urination frequency/coloration.
Bone demineralization – often symptomless initially but could lead to bone pains/breaks over time.
Immune system changes (Immune Reconstitution Syndrome) which allows for previously undetected infections to flare up upon immune restoration.

If you experience any such adverse effects from either drug regimen contact your healthcare provider immediately.

What are the most common side effects for Truvada?

Truvada, an antiretroviral medication used for HIV treatment and prevention, can cause the following side effects:

Nausea or upset stomach
Mild skin rash
Headache, dizziness
Depression or anxiety symptoms
Insomnia or other sleep problems
Fatigue and muscle pain
Change in the color of your skin (pale)
Weight loss -Truvada may also cause kidney problems – this could result in increased urination or difficulty passing urine. It's important to note that while these side effects can be distressing, they are usually manageable and often subside with time. However, any severe reactions should be reported to a healthcare professional immediately.

Are there any potential serious side effects for Truvada?

While Truvada is generally well-tolerated, like all medications it has the potential for side effects. If you experience any of these severe symptoms while taking Truvada, seek medical attention immediately:

Signs of a serious allergic reaction such as: hives; difficulty breathing; swelling of your face, lips, tongue or throat
Liver problems - including nausea, upper stomach pain, itching, tiredness or flu-like symptoms and jaundice (yellowing of the skin or eyes)
Kidney problems - little or no urination; painful or difficult urination; swelling in your feet or ankles; feeling tired or short of breath
Lactic acidosis - unusual muscle pain and weakness, trouble breathing, stomach discomforts followed by cold feeling in limbs and dizziness
Other mood changes including depression with thoughts about suicide

Please remember that this is not an exhaustive list. Always consult with a healthcare provider if you have concerns regarding medication use.

Contraindications for Triumeq and Truvada?

Both Triumeq and Truvada, like all antiretroviral medications, can cause side effects that range from moderate to severe. If you notice any worsening of symptoms or unusual physical discomforts while on these medications, it's crucial to seek medical attention promptly.

Neither Triumeq nor Truvada should be taken if you are using other medicines without your physician's knowledge. This includes over-the-counter drugs as well as prescription ones. Certain drugs for conditions such as hepatitis B and C, tuberculosis, seizures or heart issues may interact negatively with both Triumeq and Truvada.

Always inform your healthcare provider about the full list of medications you're currently taking; some may require a period of discontinuation before starting either Truvada or Triumeq in order to avoid dangerous interactions. Also note that liver function tests might be needed prior to initiating treatment with these antiretrovirals due to potential hepatotoxicity risks.

How much do Triumeq and Truvada cost?

For the brand name versions of these drugs:

The price for a 30-tablet supply of Triumeq (abacavir/dolutegravir/lamivudine) averages around $3,000. This works out to about $100/day, as only one tablet is taken daily.
The price for a 30-tablet supply of Truvada (emtricitabine/tenofovir disoproxil fumarate) is approximately $2,000. This also equates to roughly $67/day based on once-daily dosing.

Thus, if cost is a major consideration for you, then brand-name Truvada would be less expensive on a per-day treatment basis than Triumeq. However, always remember that cost should not be your primary concern in determining which drug is best suited to manage your condition.

As of now there are no generic versions available in the U.S. for either Triumeq or Truvada; however there has been approval by the FDA for generic versions and they may become available soon which could significantly lower costs.

Popularity of Triumeq and Truvada

Triumeq, composed of abacavir, dolutegravir and lamivudine, was estimated to have been prescribed to about 140,000 people in the US in 2020. Triumeq accounted for just over 12% of HIV antiretroviral prescriptions in the US. However, it appears to be a more recent addition (approved by FDA in 2014) among combination therapy medications for HIV patients. Since its introduction into the market, Triumeq has been generally increasing in prevalence.

Truvada, a combination of emtricitabine and tenofovir disoproxil fumarate is not only used as an antiretroviral treatment but also as pre-exposure prophylaxis (PrEP) against HIV infection. In this capacity Truvada was prescribed to around 200,000 people as PrEP alone in USA during the year 2019-2020. As an overall prescription drug including those taking it for treating HIV infection it accounts for just under half of antiretroviral prescriptions issued nationwide which makes up a substantial percentage when considering all medication prescribed within this context. Over recent years we have seen relatively steady prescription rates with minor fluctuations.

Conclusion

Both Triumeq and Truvada have been extensively used in the management of HIV infection, supported by numerous clinical studies showing their efficacy over placebo treatments. In some instances these medications can be combined, but this requires careful consideration by a healthcare provider due to potential contraindications. Their different mechanisms of action mean they are prescribed under varying circumstances; Triumeq works by blocking the reverse transcriptase enzyme whereas Truvada inhibits both reverse transcriptase and integrase enzymes.

Triumeq is typically considered as a first-line treatment option for naive patients or those switching from another regimen, while Truvada is often employed as part of pre-exposure prophylaxis (PrEP) to prevent HIV infection in high-risk individuals or as an adjuvant therapy with other antiretroviral drugs.

Both medications are available in generic form which represents significant cost savings especially for patients paying out-of-pocket. Both Triumeq and Truvada may require an adjustment period where side effects might become apparent before subsiding.

Side effect profiles between the two drugs are similar with both being generally well-tolerated; however, each carries unique risks such as hypersensitivity reactions with abacavir (a component of Triumeq) and bone density reduction or renal impairment with tenofovir disoproxil fumarate (a component of Truvada). Patients must closely monitor their health status when starting treatment and seek medical help immediately if adverse symptoms persist.